{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:56Z","timestamp":1783416356809,"version":"3.54.6"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The accurate classification of retroperitoneal neoplasms remains challenging, particularly when distinguishing between epithelioid leiomyoma and perivascular epitheloid cell tumor (PEComa) due to significant histological and immunohistochemical overlap. This distinction carries profound therapeutic implications, as leiomyomas are benign while PEComas possess malignant potential. The diagnostic dilemma is compounded by the documented phenomenon of aberrant HMB45 expression in otherwise conventional leiomyomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 47-year-old woman presented with an incidentally discovered right retroperitoneal mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Following complete surgical resection, pathological examination revealed a tumor composed of uniform epithelioid cells with minimal atypia, exceptionally low mitotic activity (1\/entire specimen), and low Ki-67 index (2%). Immunohistochemistry showed strong diffuse smooth muscle marker expression (Desmin, h-Caldesmon) but focal HMB45 positivity. Despite this atypical immunophenotype, the diagnosis favored epithelioid leiomyoma based on predominant benign features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>A multidisciplinary team recommended against adjuvant therapy, implementing instead a structured surveillance protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient remains disease-free after\u2005&gt;\u20054 years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case suggests that, for carefully selected patients with retroperitoneal tumors exhibiting focal HMB45 expression yet predominant benign histological features, a risk-adapted management strategy of complete surgical resection followed by active surveillance may represent a feasible and safe approach. The favorable long-term outcome provides supportive evidence that prioritizing biological behavior over diagnostic nomenclature alone can avoid overtreatment while maintaining oncologic safety. It should be acknowledged that, in the absence of confirmatory molecular studies, the favored diagnosis of epithelioid leiomyoma cannot be considered definitive and PEComa remains a differential consideration. This strategy may serve as a reference for managing similar lesions in the diagnostic gray zone, though larger cohort studies are required to further validate this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048916","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:05Z","timestamp":1779469265000},"page":"e48916","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A diagnostic dilemma between epithelioid leiomyoma and PEComa in the right retroperitoneum: A case report of risk-adapted management with long-term recurrence-free follow-up"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1061-736X","authenticated-orcid":false,"given":"Yangqing","family":"Cui","sequence":"first","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Liang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Liu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4005-9416","authenticated-orcid":false,"given":"Gangling","family":"Su","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine, Guangzhou, China"},{"name":"The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1245\/s10434-022-11864-y","article-title":"Management of locally recurrent retroperitoneal sarcoma in the adult: an updated consensus approach from the transatlantic Australasian Retroperitoneal Sarcoma Working Group.","volume":"29","author":"Tseng","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft Tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"von Mehren","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.3390\/curroncol30050349","article-title":"Surgical management of retroperitoneal sarcoma.","volume":"30","author":"Dominguez","year":"2023","journal-title":"Curr Oncol"},{"key":"R4-20260707","first-page":"415","article-title":"Perivascular epithelioid cell tumour (PEComa) of the soft tissue.","volume":"38","author":"Mai","year":"2006","journal-title":"Pathology (Phila)"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jmig.2009.04.017","article-title":"Perivascular epithelioid cell neoplasms: a systematic review of prognostic factors.","volume":"16","author":"Zekry","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"110332","DOI":"10.1016\/j.clinimag.2024.110332","article-title":"PEComas: a review of imaging and clinical features.","volume":"116","author":"Kinzel","year":"2024","journal-title":"Clin Imaging"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2009.05.011","article-title":"Perivascular epithelioid cell neoplasms: pathology and pathogenesis.","volume":"41","author":"Folpe","year":"2010","journal-title":"Hum Pathol"},{"key":"R8-20260707","first-page":"e88675","article-title":"Epithelioid leiomyoma of the uterus: a rare tumor mimicking malignancy.","volume":"17","author":"Prabhat","year":"2025","journal-title":"Cureus"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"100603","DOI":"10.1016\/j.gore.2020.100603","article-title":"Perivascular epithelioid cell tumors (PEComa) of the female genital tract: a challenging question for gynaecologic oncologist and pathologist.","volume":"33","author":"Gadducci","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/cancers17132185","article-title":"malignant perivascular epithelioid cell tumor (PEComa) of the uterus: a rare type of mesenchymal tumors and a management challenge.","volume":"17","author":"Oliver-Perez","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4132\/jptm.2016.04.20","article-title":"A case of malignant PEComa of the uterus associated with intramural leiomyoma and endometrial carcinoma.","volume":"50","author":"Choi","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jjco\/hyaf056","article-title":"PEComa-its clinical features, histopathology, and current therapy.","volume":"55","author":"Izubuchi","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 1","key":"R13-20260707","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1038\/modpathol.2015.139","article-title":"Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.","volume":"29","author":"Oliva","year":"2016","journal-title":"Mod Pathol"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"1610831","DOI":"10.3389\/pore.2022.1610831","article-title":"Angiomyolipoma of the kidney-clinicopathological analysis of 52 cases.","volume":"28","author":"Fejes","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/curroncol32060352","article-title":"Mucinous cystic neoplasms in male patients: histopathological and molecular diagnoses.","volume":"32","author":"Malaspina","year":"2025","journal-title":"Curr Oncol"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAS.0000000000001795","article-title":"Epithelioid leiomyosarcoma of the uterus: modern outcome-based appraisal of diagnostic criteria in a large institutional series.","volume":"46","author":"Chapel","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejso.2020.04.054","article-title":"Overview of primary adult retroperitoneal tumours.","volume":"46","author":"Improta","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3350\/cmh.2016.0034","article-title":"Hepatic perivascular epithelioid cell tumor (PEComa): a case report with a review of literatures.","volume":"23","author":"Son","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/PAS.0000000000001894","article-title":"PEComa-like neoplasms characterized by ASPSCR1-TFE3 fusion: another face of TFE3-related mesenchymal neoplasia.","volume":"46","author":"Argani","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"e1006242","DOI":"10.1371\/journal.pgen.1006242","article-title":"Whole exome sequencing identifies TSC1\/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development.","volume":"12","author":"Giannikou","year":"2016","journal-title":"PLoS Genet"},{"issue":"Suppl 1","key":"R21-20260707","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00292-019-0612-5","article-title":"Complexity of PEComas: diagnostic approach, molecular background, clinical management.","volume":"41","author":"Utpatel","year":"2020","journal-title":"Pathologe"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/PAS.0000000000002218","article-title":"TFE3 -rearranged PEComa\/PEComa-like neoplasms: report of 25 new cases expanding the clinicopathologic spectrum and highlighting its association with prior exposure to chemotherapy.","volume":"48","author":"Argani","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:36Z","timestamp":1783414896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048916","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}